Literature DB >> 6289735

Efficacy of a twelve-hourly ceftriaxone regimen in the treatment of serious bacterial infections.

M J Maslow, J F Levine, A A Pollock, M S Simberkoff, J J Rahal.   

Abstract

Eighteen patients with 21 serious infections were treated with ceftriaxone, 1 g intravenously every 12 h, for a mean duration of 8 days. Eighteen gram-negative and two gram-positive organisms were isolated. Sites of infection included blood (three patients), urinary tract (six patients), respiratory tract (seven patients), biliary tract (three patients), ascitic fluid (one patient), and skin (one patient). Serum, bile, and ascitic fluid concentrations of ceftriaxone were in excess of the minimal bactericidal concentration required for the infecting organism in all cases. A bacteriological response was demonstrated in 94% of the infections. A clinical response occurred in four infections from which no pathogens were recovered. In one patient, ceftriaxone failed to eradicate a peritoneal infection due to Bacteroides fragilis. In two patients, superinfection with enterococci developed both during and after therapy. Systemic tolerance to ceftriaxone was excellent.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6289735      PMCID: PMC183681          DOI: 10.1128/AAC.22.1.103

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

2.  Ro 13-9904: A cephalosporin with a high degree of activity and broad antibacterial activity: an invitro comparative study.

Authors:  R Wise; A P Gillett; J M Andrews; K A Bedford
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

3.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

4.  LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.

Authors:  G M Trager; G W White; V M Zimelis; A P Panwalker
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

5.  Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.

Authors:  M Seddon; R Wise; A P Gillett; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

6.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

7.  In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases.

Authors:  K Shannon; A King; C Warren; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

8.  Comparative in-vitro activity and mode of action of ceftriaxone (Ro 13-9904), a new highly potent cephalosporin.

Authors:  M J Hall; D Westmacott; P Wong-Kai-In
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

9.  In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin.

Authors:  G Beskid; J G Christenson; R Cleeland; W DeLorenzo; P W Trown
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

10.  In vitro evaluation of Ro 13-9904.

Authors:  A M Hinkle; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

View more
  7 in total

Review 1.  Pathogenicity of the enterococcus in surgical infections.

Authors:  P S Barie; N V Christou; E P Dellinger; W R Rout; H H Stone; J P Waymack
Journal:  Ann Surg       Date:  1990-08       Impact factor: 12.969

2.  In vitro activity of ceftriaxone and other cephalosporins against 602 clinical isolates of staphylococci from geographically diverse medical centers.

Authors:  M A Pfaller; A L Barry; L D Sabath; B N Kreiswirth; P R Murray; P C Fuchs; J C McLaughlin
Journal:  Eur J Epidemiol       Date:  1993-11       Impact factor: 8.082

Review 3.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

4.  Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis.

Authors:  T Y Ti; L Fortin; J H Kreeft; D S East; R I Ogilvie; P J Somerville
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

5.  Once-daily ceftriaxone for skin and soft tissue infections.

Authors:  F M Gordin; C B Wofsy; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

Review 6.  Infections due to antibiotic-resistant gram-positive cocci.

Authors:  G M Caputo; M Singer; S White; M R Weitekamp
Journal:  J Gen Intern Med       Date:  1993-11       Impact factor: 5.128

Review 7.  Clinical pharmacokinetics of ceftriaxone.

Authors:  J H Yuk; C H Nightingale; R Quintiliani
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.